← Back to Home

Engineering NK Cells Inside the Body: Nanoparticles Show Potential for Cancer Treatment and Immunotherapy in Mice

Researchers used lipid nanoparticles to deliver mRNA, giving natural killer cells inside mice a new ability to recognize targets. Models of blood cancer and autoimmune hepatitis showed signs of efficacy, but the duration of the effects and immune safety still need to be clarified before human use.

By SURL BioNews

One challenge in cell therapy is that immune cells must first be taken to a laboratory for modification and expansion before being infused back into the body. A Massachusetts Institute of Technology team has attempted to move the modification step directly into the body: lipid nanoparticles carry genetic instructions that enable natural killer cells (NK cells) inside mice to produce chimeric antigen receptors (CARs), giving them the ability to recognize and attack designated cells. The study was published on October 13 in *Nature Biotechnology*, and the evidence remains limited to animal experiments.

The key is delivering the instructions to the right place. The team equipped the particle surfaces with engineered antibody fragment ligands that recognize receptors on NK cells, promoting particle uptake and delivering CAR-encoding messenger RNA (mRNA) into the cells. The study reported NK cell transfection rates of up to approximately 80% in mouse experiments. This figure describes delivery efficiency; it does not mean that 80% of tumors were eliminated, nor is it a treatment success rate in humans.

The choice of NK cells also relates to the cells targeted in disease. When researchers aim to eliminate abnormal T cells, using T cells themselves as the therapeutic tool could cause the therapeutic cells to attack one another if their CARs recognize T cell markers. NK cells offer another approach. The team first used a CAR that recognizes CD19 to eliminate B cells from the circulation of healthy mice, then used a CAR that recognizes CD3 to test whether it could address T cell-driven diseases.

In a mouse model of autoimmune hepatitis, CD3-directed CAR NK cells eliminated almost all autoreactive T cells. According to MIT's research overview, liver damage in the experimental animals was also repaired after a single injection. However, CD3 is not a marker unique to disease-causing T cells. This finding supports the feasibility of eliminating the relevant immune cells, but does not yet demonstrate that the therapy can selectively preserve normal immune function in humans.

The cancer tests went further, using mouse models of blood tumors containing human immune cells. The paper's abstract reported that particles adapted to engineer human NK cells induced tumor regression in two humanized models of hematologic malignancies. MIT also stated that, in the T cell lymphoma model, tumors were eliminated after five injections, with effects similar to those of CAR NK cells prepared outside the body and then infused. These remain tumor responses in mice and cannot be directly extrapolated to durable remission in patients.

The study also explored solid tumors, but the mechanism needs to be understood separately: this part used particles to target the inhibitory immune checkpoint NKG2A, relieving some of the tumor-mediated inhibition of NK cells. This differs from the strategy of using CARs to recognize CD19 or CD3, so all of the antitumor results cannot be attributed to a single CAR NK design.

The significance of this work lies in integrating cell modification and delivery into a platform that can operate inside the body, providing experimental evidence for simplifying cell therapy manufacturing. Before it can reach patients, researchers still need to establish how long CAR expression lasts, whether repeated dosing is necessary, and how immune recovery and safety are affected after B cell or T cell depletion. The research was led by Daniel Anderson and supported by Sanofi, the Marble Center for Cancer Nanomedicine, and a core grant from the U.S. National Cancer Institute. There is currently no evidence of this system's efficacy in humans.

References

  1. Nature Biotechnology, Published online: 2026-10-13; | doi:10.1038/s41587-026-03310-1
  2. MIT News
  3. テック・アイ生命科学